Sfoglia per Autore
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
2025 Banerjee, S; Van Nieuwenhuysen, E; Aghajanian, C; D'Hondt, V; Monk, B; Clamp, A; Prendergast, E; Oaknin, A; Ring, K; Colombo, N; Holloway, R; Rodrigues, M; Chon, H; Gourley, C; Santin, A; Thaker, P; Gennigens, C; Newman, G; Salinas, E; Youssoufian, H; Moore, K; Lustgarten, S; O'Malley, D; Van Gorp, T; Grisham, R
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
2025 Blons, H; Abdelli, J; Landman, S; Taly, V; Mulot, C; Laurent-Puig, P; You, B; Harter, P; Lorusso, D; Garcia-Garcia, Y; Polterauer, S; Hietanen, S; Colombo, N; Vergote, I; Kobayashi, H; De La Motte Rouge, T; Buderath, P; Cecere, S; Bataillon, G; Pujade-Lauraine, E; Ray-Coquard, I
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
2025 Lorusso, D; Colombo, N; Dubot, C; Cáceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüş, M; Olivera, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Li, K; Toker, S; Tekin, C; Tewari, K; Monk, B
Erratum to ‘Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001896), (10.1016/j.ijgc.2025.101664))
2025 Fumagalli, D; Jayraj, A; Olearo, E; Capasso, I; Hsu, H; Tzur, Y; Piedimonte, S; Jugeli, B; Santana, B; De Vitis, L; Caruso, G; Aletti, G; Colombo, N; Ramirez, P
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
2025 Lorusso, D; Xiang, Y; Hasegawa, K; Scambia, G; Leiva, M; Ramos-Elias, P; Acevedo, A; Cvek, J; Randall, L; De Santana Gomes, A; Mejia, F; Helpman, L; Akilli, H; Lee, J; Saevets, V; Zagouri, F; Gilbert, L; Sehouli, J; Tharavichitkul, E; Lindemann, K; Colombo, N; Chang, C; Bednarikova, M; Zhu, H; Oaknin, A; Christiaens, M; Petru, E; Usami, E; Liu, P; Yamada, K; Toker, S; Keefe, S; Pignata, S; Duska, L
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
2025 Scambia, G; Villalobos Valencia, R; Colombo, N; Cibula, D; Leath, C; Bidzinski, M; Kim, J; Nam, J; Madry, R; Hernandez, C; Mora, P; Ryu, S; Ah-See, M; Lowe, E; Lukashchuk, N; Carter, D; Penson, R
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 Oaknin, A; Monk, B; de Melo, A; Kim, H; Kim, Y; Lisyanskaya, A; Samouëlian, V; Lorusso, D; Damian, F; Chang, C; Gotovkin, E; Takahashi, S; Ramone, D; Maćkowiak-Matejczyk, B; Polastro, L; Alia, E; Colombo, N; Makarova, Y; Goh, J; Hasegawa, K; Mora, P; Pikiel, J; Srivastav, R; Rischin, D; Rubio, M; Perez, J; Yoo, S; Gao, B; Jamil, S; Seebach, F; Lowy, I; Mathias, M; Fury, M; Tewari, K
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
2025 Quesada, S; Penault-Llorca, F; Matias-Guiu, X; Banerjee, S; Barberis, M; Coleman, R; Colombo, N; Defazio, A; Mcneish, I; Nogueira-Rodrigues, A; Oaknin, A; Pignata, S; Pujade-Lauraine, É; Rouleau, É; Ryška, A; Van Der Merwe, N; Van Gorp, T; Vergote, I; Weichert, W; Wu, X; Ray-Coquard, I; Pujol, P
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
2025 Bogani, G; Moore, K; Ray-Coquard, I; Lorusso, D; Matulonis, U; Ledermann, J; González-Martín, A; Kurtz, J; Pujade-Lauraine, E; Scambia, G; Caruso, G; Raspagliesi, F; Colombo, N; Monk, B
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
2025 Matulonis, U; Herrstedt, J; Oza, A; Mahner, S; Redondo, A; Berton, D; Berek, J; Haslund, C; Marme, F; Gonzalez-Martin, A; Becourt, S; Tinker, A; Ledermann, J; Benigno, B; Lindahl, G; Colombo, N; Malinowska, I; Liu, W; Bains, M; Monk, B; Mirza, M
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status: Clinical Studies
2025 Pignata, S; Oza, A; Hall, G; Pardo, B; Madry, R; Cibula, D; Klat, J; Montes, A; Glasspool, R; Colombo, N; Pete, I; Herrero Ibanez, A; Romeo, M; Ilieva, R; Timcheva, C; Di Maio, M; Bashir, Z; Taylor, R; Barnicle, A; Clamp, A
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer
2025 Caruso, G; Kumar, A; Langstraat, C; Mcgree, M; Fought, A; Harrington, S; Nasioudis, D; Aletti, G; Colombo, N; Giuntoli, R; Cliby, W
Systems epigenetic approach towards non-invasive breast cancer detection
2025 Herzog, C; Theeuwes, B; Jones, A; Evans, I; Bjørge, L; Zikan, M; Cibula, D; Harbeck, N; Colombo, N; Pashayan, N; Widschwendter, M
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation
2025 Konstantinopoulos, P; Kim, J; Freyer, G; Lee, J; Gaba, L; Grisham, R; Colombo, N; Wu, X; Sehouli, J; Cruz, F; Cibula, D; Monk, B; Nyvang, G; Friedlander, M; Lorusso, D; Van Nieuwenhuysen, E; Malik, R; Glasspool, R; Marth, C; Leary, A; Cortés-Salgado, A; Zamagni, C; Marmé, F; Sufliarsky, J; Hinson, P; Zuradelli, M; Wang, C; Su, F; Paule, I; Miller, M; Matulonis, U; González-Martín, A
Predictors of recurrence in early-stage cervical cancer without adjuvant treatment after radical surgery
2025 Caruso, G; Gaiano, M; De Vitis, L; Stefani, E; Rosanu, M; Ribero, L; Alessi, S; Petralia, G; Casarin, J; Gandini, S; Maggioni, A; Aletti, G; Zanagnolo, V; Colombo, N; Schivardi, G; Multinu, F
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
2025 Riva, C; Minetto, P; Chies, M; Vernarecci, C; Colombo, N; Rosellini, S; Parodi, A; Tedone, E; Carminati, E; Nurra, C; Puglisi, F; Frello, M; Maio, E; Ferro, B; Zecchetti, G; Fugazza, G; Nozza, P; Cea, M; Lemoli, R; Guolo, F
Uterine leiomyosarcoma
2025 Bogani, G; Caruso, G; Ray-Coquard, I; Ramirez, P; Concin, N; Ngoi, N; Coleman, R; Mariani, A; Cliby, W; Leitao, M; Rustum, N; Casali, P; Gronchi, A; Vergote, I; Kroep, J; Enomoto, T; Takehara, K; Denys, H; Takano, M; Provencher, D; Wimberger, P; Kim, S; Kim, J; Zannoni, G; Tan, D; Casarin, J; Paolini, B; Chiappa, V; Raspagliesi, F; Cuccu, I; Di Donato, V; O'Malley, D; Mutch, D; Brown, J; Herrera, F; Colombo, N; Pignata, S; Scambia, G; Slomovitz, B; Monk, B
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 Olawaiye, A; Gladieff, L; O'Malley, D; Kim, J; Garbaos, G; Salutari, V; Gilbert, L; Mileshkin, L; Devaux, A; Hopp, E; Lee, Y; Oaknin, A; Scaranti, M; Kim, B; Colombo, N; Mccollum, M; Diakos, C; Clamp, A; Leiser, A; Balazs, B; Monk, B; Scandurra, G; Mcclung, E; Kaczmarek, E; Slomovitz, B; De La Cueva, H; De Carvalho Calabrich, A; Cassani, C; You, B; Van Gorp, T; Churruca, C; Caruso, G; Nicum, S; Bagameri, A; Artioli, G; Bodnar, L; Kang, S; Vergote, I; Kesner-Hays, A; Pashova, H; Pai, S; Tudor, I; Jubb, A; Lorusso, D
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer
2025 De Vitis, L; Schivardi, G; Gaeta, A; Caruso, G; Rosanu, M; Ribero, L; Fumagalli, D; Casarin, J; Betella, I; Bogani, G; Langstraat, C; Aletti, G; Colombo, N; Zanagnolo, V; Gandini, S; Multinu, F
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025 Valenza, C; Mongillo, M; Visconti, M; Katrini, J; Trapani, D; Boldrini, L; Guidi, L; Farfalla, A; Malengo, D; Caruso, G; Derio, S; Lapresa, M; Parma, G; Biagioli, E; Omodeo Salé, E; Curigliano, G; Colombo, N
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile